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Abstract
In recent years there have been a lot of interest to test for similarity between bio-
logical drug products, commonly known as biologics. Biologics are large and complex
molecule drugs that are produced by living cells and hence these are sensitive to the
environmental changes. In addition, biologics usually induce antibodies which raises
the safety and efficacy issues. The manufacturing process is also much more com-
plicated and often costlier than the small-molecule generic drugs. Because of these
complexities and inherent variability of the biologics, the testing paradigm of the
traditional generic drugs cannot be directly used to test for biosimilarity. Taking into
account some of these concerns we propose a functional distance based methodology
that takes into consideration the entire time course of the study and is based on a
class of flexible semi-parametric models. The empirical results show that the pro-
posed approach is more sensitive than the classical equivalence tests approach which
are usually based on arbitrarily chosen time point. Bootstrap based methodologies
are also presented for statistical inference.
Keywords: Binary Responses; Bernstein Polynomials; Rheumatic Arthritis; Semiparamet-
ric Models
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1 Introduction
Biosimilars is referred to as the similarity between biological drug products. Biologics are
large and complex molecule drugs that are produced by living cells. They have heterogene-
ity structures and are sensitive to the environmental changes. In addition, biologics usually
induce antibodies which raises the safety and efficacy issues. The manufacturing process
is also much more complicated and costly than the small-molecule generic drugs. Due to
such nature of biologics, the assessment of biosimilar products is fundamentally different
from the generic small-molecule drug products. With the small-molecule drug, the chemical
formula is normally known and can be recreated exactly the same as the innovator drug,
hence randomized clinical trials are routinely not required for the approval. Because of
the complexity and the variability of the biologics, the paradigm of the traditional generic
drugs cannot be directly extended to biosimilars. Further details on biosimilars can be
seen in guidance FDA (2012), and statistical literatures such as Liao and Heyse (2011),
Endrenyi et al. (2013) and Chow (2013).
To establish the biosimilarity between the test drug and the innovator, a biosimilar
manufacturer needs to show the equivalence in both of the pharmacokinetic (PK) and
pharmacodynamic (PD) parameters, and the therapeutic effects. The equivalence of PK
parameters, such as the area under the curve (AUC) and the maximum observed concen-
tration (Cmax), can be determined similarly to the generic drugs using the classic average
bioequivalence rule, in which bioequivalence can be claimed when the 90% confidence in-
terval for the estimated ratio of geometric mean (GMR) of the parameters lies between
the limits 0.80 and 1.25 (see Food et al. (2001)). This classic bioequivalence rule can also
be challenging for the biologics to pass, as biologics are far more variable than usual small
molecule drugs. Some reference scale approaches for biosimilarity which take the reference
variability into consideration have been proposed by Haidar et al. (2008), Haidar et al.
(2008), and Liao and Heyse (2011). However, it is more challenging when it comes to the
equivalence based on clinical endpoints, and no statistical approach has been well-defined.
Classically, the equivalence of therapeutic effects can be declared if the difference be-
tween the means of the primary endpoints for two drugs is less than a pre-specified non-
inferiority limit, with 95% confidence. However, for biological drugs, this approach can
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result in large sample size, which is against the goal to reduce the expense of the biosimilar
product. Moreover, the biosimilarity based on the primary endpoints is only established
at one single time point, typically when the maximal effect is achieved by the innovator.
However, it could be possible that differences can be observed at early, non-saturated time
points. Such differences before the primary time point cannot be captured by this approach.
To overcome this disadvantage, we propose a functional distance based methodology
that takes into consideration of the entire time course. Although our proposed methodology
is applicable to many types of diseases and similar scenarios, we illustrate our methodology
for the disease rheumatoid arthritis (RA) as a case study. In recent years, treatment of RA
has gained increasing interest in the pharmaceutical industry. Many biologics have been
developed and used in clinical trials including etanercept, adalimumab (HUMIRA), inflix-
imab, golimumab, tocilizumab, abatacept, and certolizumab, some of these have generated
multi-billion revenue per year for the pharmaceutical companies. As a result of large profit,
there is large interest in developing innovator biological drugs, and biosimilar drugs.
In Section 2, we introduce the proposed functional metrics and present two classes of
modeling techniques. Section 3 is devoted to estimation methods for fitting such models
and thus estimators for functional metrics. In Section 4, we explore several simulation
experiments to investigate the performance of these estimators. In Section 5, we apply the
proposed functional metrics to various Rheumatoid Arthritis Trials data sets for illustra-
tion. Finally in Section 6, we make some concluding remarks and discussion on possible
extensions.
2 Functional Metrics to Assess Biosimilarity
In a treatment group with nj subjects, let Yj(t) denote the number of subjects that achieves
some clinical event at time t for group j = 1, . . . , J . Assuming that the trials were performed
independently for each group, we postulate the familiar binary response model:
Yj(t) ∼ Bin{nj, θj(t)}, for t ≥ 0, (1)
where θj(t) is the response rate function for group j = 1, . . . , J .
When there are only J = 2 groups, we write the (additive) difference of response rates
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as a function of time ∆(t) = θ2(t) − θ1(t). Notice that the difference in rates is allowed
to vary with time t in contrast to traditional approach which usually chooses a specific
time point t0 and uses fixed difference ∆0 = ∆(t0) to decide the difference between two
response rates at a fixed time point t = t0. Many other discrepancies between these rates
can also be used (e.g., relative difference, odds ratio or log odds ratio), if so desired and the
proposed methodology can easily be extended to such alternative (time varying) measures
of discrepancies.
Taking a more dynamic approach, we propose a functional metric Lp(a, b) that takes
into account the entire time interval to compare the groups at a chosen interval of time.
We define the functional metric as follows:
Lp(a, b) =
(∫ b
a
|∆(t)|pdt
) 1
p
, p ≥ 1 and a, b ⊆ [0,∞). (2)
In practice, it is common to choose p = 1, 2 and ∞, representing L1, L2 and L∞ norms.
Notice that L∞(a, b) = max
a
|∆(t)|. Although the user needs to choose a sub-interval (a, b)
based on the therapeutic considerations for a specific drug and trail, one can mitigate
the effect to some effect by considering the scaled metric Lp(a, b)/(b − a), which would
remain relatively stable with respect to the interval length b − a. For common dose-
response relationship, it is often assumed that the true response rate function θ0(t) satisfy
the following conditions:
(i) θ0(·) is continuous in [0,∞);
(ii) θ0(0) = 0, and θ0(∞) ≤ 1;
(iii) (optional) θ(t1) ≤ θ(t2), for 0 ≤ t1 ≤ t2 ≤ ∞.
Condition (iii) is the monotonic shape constraint on the entire time interval, which could
be dropped or relaxed depending on type of clinical trials and associated drugs under such
studies. Our goal is to obtain estimate of the functional metric by suitably modeling the
true response rates for each group as flexibly as possible while satisfying the above mild
regularity conditions.
Given a chosen value for the triplet (p, a, b), often the goal is to develop statistical
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inference procedure to test the following non-inferiority hypotheses
H0 : Lp(a, b) > d(p; a, b) vs. HA : Lp(a, b) ≤ d(p; a, b),
where the non-inferiority margin d(p; a, b) is determined by medical practitioners to achieve
the desired power of the test.
Remark: We would like to point out that our focus is on deriving statistical inference
procedures for the proposed functional metric Lp(a, b) given a specific non-inferiority margin
and not necessarily in determining the margin.
Nonetheless, the choice of the margin is a critical matter and should be carried out
very carefully by consulting with the regularity agencies and drug makers. Our inferential
procedures described later, does not depend on a any specific choices of this margin and
can be broadly applied to any chosen values of the triplet and the corresponding margin.
In the following subsections, we introduce two classes of models to estimate Lp(a, b):
parametric models and nonparametric models.
2.1 Parametric Models
There are a multitude of choices to model the dose response function θ(t), satisfying the
above mentioned regularity conditions and based on the type of applications, here, however
we present two popular class of parametric models that are routinely used for RA trials.
A popular and very useful class is given by the so-called exponential decay model given
by the following equation:
θE(t) = α {1− exp(−βt)} , t > 0, (3)
where α and β are unknown positive quantities to be estimated (see Reeve et al. (2013)
for further details). For θE(·) to satisfy the above three properties, we have to restrict
α ∈ (0, 1] and β > 0. We refer model form (3) as the exponential decay model. Notice that
θE(t) is a strictly increasing function of t and has an asymptote at θE(∞) = α and hence
the restriction α ≤ 1.
Another parametric form that is also used very frequently is the so-called log-logistic
model given by,
θL(t) =
(
1 + e−α−βlogt
)−1
. (4)
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θL(·) also has two unknown parameters and satisfies the three properties for any α ∈ R
and β ≥ 0. Notice that θL(t) is also a strictly increasing function with an asymptotic
θL(∞) = 1. This model has a similar shape compared with the exponential decay model
as shown in Figure 1 and Figure 2.
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Figure 1: A demonstration of exponential decay curves with α1 = 0.6, β1 = 0.2 and α2 =
0.9, β2 = 0.08.
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Figure 2: A demonstration of log-logistic curves with α1 = −0.5, β1 = 0.3 and α2 =
−2, β2 = 1.
In subsequent parametric likelihood based analysis, we will assume that the response
rate functions are modeled using either exponential decay model or the log-logistic model
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and then we can compute the difference ∆(t) using numerical integration methods (e.g.,
Gaussian quadrature methods using the R function integrate) given a value of the two
parameters (α, β) in either cases, be it for the true value or estimated values of these
parameters, when performing simulation studies or analyzing case studies, respectively.
2.2 Nonparametric Models
A well-known shortcoming of using parametric models is that specifying an incorrect para-
metric form leads to bias and inefficient estimation. Therefore, a more flexible functional
form is desirable as the true underlying treatment effect model is most likely unknown.
Bernstein polynomial basis can be used in function estimation with shape restriction. A
Bernstein polynomial of degree M is given by
BM(x,η) =
M∑
k=0
ηkbM(x, k), (5)
where bM(x, k) =
(
M
k
)
xk(1 − x)1−k, which is the binomial probability mass function or
equivalently can be viewed as the kernel of a Beta (distribution) density function.
Let Tmin and Tmax be the time range with 0 ≤ Tmin < Tmax < ∞. We consider the
following functional form (see Shin and Ghosh (2017) for details).
θM(t;η, Tmax, Tmin) =

0, t ≤ Tmin∑M
k=1 ηkbM
(
t−Tmin
Tmax−Tmin , k
)
, Tmin < t < Tmax
ηM + (1− ηM) t−Tmaxt−Tmax+1 , t ≥ Tmax
(6)
with the constraint
0 ≤ η1 ≤ · · · ≤ ηM ≤ 1.
A computational convenient reparametrization of (6) is to define η0 = 0 and γk =
ηk − ηk−1, so that ηk =
∑k
i=1 γi and (5) can be re-write as
BM(x,η) =
M∑
k=1
ηkbM(x, k) =
M∑
k=1
(
k∑
l=1
γl
)
bM(x, k) =
M∑
l=1
γlFM(x; l),
where FM(x; l) =
∑M
k=l bM(x, k). The benefit of this reparametrization is that we now
express θM(t) as a linear model:
θM(t;γ) = FM
(
t− Tmin
Tmax − Tmin
)τ
γ,
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where FM(x) = (FM(x, 1), . . . , FM(x,M))
τ denotes vector of basis functions. A convenient
fact about FM(x; l) is
FM(x; l) =
∫ x
0
ul−1(1− u)M−l
B(l,M − l + 1)du,
which is the cumulative density distribution of a Beta(l,M − l + 1) random variable. The
parameter η can be estimated by maximum likelihood methods, which we will discuss in
section 3.2.
A well known fact about the Bernstein basis is that it provides uniform approxima-
tion of a continuous function on a compact interval. More specifically, by choosing ηk =
θ0(k(Tmax−Tmin)/M) in equation (6) one can show that supt∈[Tmin,Tmax] |θM(t;η, Tmax, Tmin)−
θ0(t)| → 0 as M → ∞ (see Lorentz (2012)). Rate of convergence can also be obtained by
assuming further regularity conditions on the true understing dose response function θ0(t).
These well known results together with the sieve based estimation techniques presented in
Geman and Hwang (1982) and Shen and Wong (1994) can be used to derive the consistency
of our proposed methods described in the next section. However, we omit the technical
details in this paper.
3 Estimation Methods
3.1 Maximum Likelihood for Parametric Models
Once we specified the functional form of θ(t), we can get maximum likelihood estimates
(MLEs) of the model parameters (αj, βj) for each treatment arm by maximizing the log-
likelihood
l(αj, βj) =
Nj∑
i=1
Yj(ti)log(θ(ti;αj, βj)) + (nj − Yj(ti))log(1− θ(ti;αj, βj)), j = 1, 2, (7)
where Nj is the number of time points that we have observations for each treatment arm j.
The estimated treatment effect curve is obtained by plugging in the maximum likelihood
estimates of parameters for each treatment arm,
∆̂(t; αˆ1, βˆ1, αˆ2, βˆ2) = θ(t; αˆ2, βˆ2)− θ(t; αˆ1, βˆ1).
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The proposed function metric Lp(a, b) is then estimated by plugging in the estimated
treatment effect curve,
Lˆp(a, b; αˆ1, βˆ1, αˆ2, βˆ2) =
(∫ b
a
|∆̂(t; αˆ1, βˆ1, αˆ2, βˆ2)|pdt
) 1
p
, p ≥ 1 and a, b ⊆ [0,∞),
which can be easily computed by numerical integration method. The corresponding esti-
mates of the standard errors of the MLEs and hence the associated confidence intervals can
be obtained using the standard so-called delta-method using standard large sample theory
(e.g., see Casella and Berger (2002)). But such methods can lead to complicated expres-
sion and may require numerical derivative and integration calculations. Alternatively, we
use the standard parametric bootstrap methods to derive the sampling distributions of the
estimates of ∆(t) and hence obtain the standard errors and confidence intervals.
3.2 Approximate Likelihood Methods for Nonparametric Models
Similar to parametric models, the estimation can be done by maximizing the log-likelihood
(7) where we substitute θ(α, β) by θM(η) for a fixed M and then vary M as a function of the
sample size n to derive the nonparametric estimate of ∆(t). However, such a method can
be computationally demanding due to nonlinear optimization subject to linear inequality
constraints on η.
An alternative method, which is more computationally efficient, is to use the normal ap-
proximate likelihood methods, when sample size n is moderately large. Using the standard
normal approximation of the Binomial likelihood, it follows that the distribution of esti-
mated response probability θ(t) can be approximated by the following normal distribution
√
nj
{
θˆj(t)− θj(t)
}
∼ N [0, θj(t){1− θj(t)}] , j = 1, 2, (8)
where θˆj(t) = Yj(t)/nj is the empirical nonparametric estimate of θj(t). In the case of
Yj(t) = 0, one can use Anscombe corrected empirical proportion given by θˆj(t) =
Yj+3/8
nj+3/4
which has been shown to have second order accuracy in estimating the true response rate
function. To account the non-constant variance of the normal distribution, we will adopt
a weighted least square method by replacing the true variance by its empirical estimate.
The estimation problem now can be cast as a standard linear regression model, where θˆj(t)
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serves as the response variable and FMj(t) serves as the predictors. The estimation of
parameters γj is now turns into a constrained weighted least square problem
min
γj
Nj∑
i=1
wij
{
θˆj(ti)− FMj(ti)′γj
}2
subject to Rγj ≥ b, j = 1, 2.
The weight wij can be estimated by wˆij = nj/
[
θˆj(ti){1− θˆj(ti)}
]
for j = 1, 2. To satisfy
the properties in section 2, a specific configuration is to let
R =
 IM
−1′M
γj and b =
0M
−1
 .
This optimization problem can be easily solved by any standard quadtratic programming
techniques (e.g., using quadprog package in the R software) and hence obtain computa-
tionally efficient estimates of γ̂j and hence that of η̂j. Recall that, all of these estimation
can be done relatively easily for a fixed chosen value of the tuning parameter M which
required to increase with the sample size n.
This key issue of the selecting the degree of Bernstein polynomial, M is tricky and we
propose a practical approach based on suitable metric to choose M which depends on data.
We formally propose a method to make this selection in section 3.3. For now, we assume
the M values are pre-determined using the metric.
Once suitable M is determined separately for both treatment groups, we get functional
estimates θ̂1(·; γ̂1) = θM1(·; γ̂1) and θ̂2(·; γ̂2) = θM2(·; γ̂2). Similar as parametric models,
the plugged in estimator of functional metric Lp(a, b) is
Lˆp(a, b; γ̂1, γ̂2) =
(∫ b
a
|θ̂2(t; γ̂1)− θ̂1(t; γ̂2)|pdt
) 1
p
, p ≥ 1 and a, b ⊆ [0,∞).
3.3 Selection of M via Kolmogorov-Smirnov metric
We provide a principled way to select the Bernstein polynomial degree M from the observed
data. The idea here is to use the Kolmogorov-Smirnov (KS) metric to make data-driven
decision for polynomial degree selection. Notice that we have used the normal approxima-
tion of empirical estimates of the response rate function to derive the estimate of η and so
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if an M is selected that makes the normal approximation superior across different choices
of M , the estimate of η will also likely to be better in approximating the true response rate
function.
Using the above intuitive principle, given the approximate likelihood given in (8), we
can construct a vector of standardized residuals which are likely to be N(0, 1) distributed
variables
Zi(m) =
√
n
{
θˆ(ti)− θˆm(ti)
}
θ(ti){1− θ(ti)} , i = 1, . . . , N,
where n is sample size, N is the number of time points and θˆm(ti) is the fitted value
obtained from a Bernstein polynomial of degree m. We want to find the smallest m such
that the resulting Zi(m) are as closely approximately normally distributed as possible.
Recall that here we are not trying to test for normality, but rather using the KS metric to
select ‘optimal’ degree m that minimizes the KS metric over a given set of values of m. As
the KS metric can take on any positive value, we use the equivalent p-value of the KS test
which is automatically scaled to be between 0 and 1. Clearly, the closer the p-value is to 1
the better the standardized residuals match with a N(0, 1) distribution. Therefore, we we
compute the p-value of the KS test for m = 2, . . . , d N
log(N)
e (Babu et al. (2002)) and select
Mˆopt = m whenever the p-value of the test is greater or equal to our pre-specified critical
value α ∈ (0, 1). A default value for α = 0.2 is reasonable in practice but we explore its
sensitivity using simulation studies in selecting the optimal M .
4 Simulation Study
In this section, the performance of the proposed function metrics are investigated under
several functional forms using simulated data sets. We explore and compare two categories
of models, namely parametric models and nonparametric models. All results in this section
are based on 1000 Monte Carlo repetitions.
We simulate two treatment group by the exponential decay model (3) with α1 =
0.6, β1 = 0.2 and α2 = 0.9, β2 = 0.08 respectively. The time horizon is set to be [0, 30].
We simulate an observation of the response rate in every 1 or 2 time units. Therefore, the
number of observations we have for each treatment group is N = 16 or N = 31 respectively.
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To evaluate functional metric Lp(a, b), time boundary a = 5, b = 20 and L1 norm (p = 1)
are used through out this section. This generative model and the corresponding L value is
demonstrated in Figure 3 and these choices are motivated by the real case studies that we
illustrate in the next section.
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Figure 3: Response rate curves of the two groups used for simulation. The L1(5, 20)
quantity is the orange shaded area plus the blue shaded area.
We compare the performance of parametric model and nonparametric model with vary-
ing sample sizes and varying number of time points settings for estimating the true func-
tional metric quantity L0 = L1(5, 20). For parametric model, the correctly specified model
is exponential decay model (3). As we are interested in exploring the effect of misspecifica-
tion of the underlying true model, a log-logistic model (4) is fitted for comparison (when the
true underlyting model is the exponential decay model), which we refer to as the misspec-
ified parametric (MP) model. Nonparametric model is implemented by the approximate
likelihood method introduced in section 3.2. The polynomial degree is selected according
to the method introduced in section 3.3.
To compare performance of the proposed estimators, we define the relative bias (RB)
of estimator Lˆ as RB(Lˆ) = (Lˆ− L0)/L0, where L0 is the true value of the L1 metric. The
results comparing the values of RB of Lˆ under different functional forms are reported in
Table 1. Boxplots of RBs (across 1000 MC runs) are shown in Figure 4 and Figure 5. A
summary of the selected values of M is reported in Table 2.
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Note that the log-logistic model (4) has very similar shape compared to the exponential
model (3); however, the parametric estimator using log-logistic model still demonstrates a
high notable bias (in terms of RB) as can be seen in Table 1. Nonparametric methods are
shown to give relatively unbiased estimates of the functional metric, and have competitive
performance comparing it to the correctly specified parametric model. As expected when
the sample size n and number of sampling points N increases, the RB of the L metric
under MP tends to increase while those under TP and NP shrinks. This is a well-known
phenomenon of using MLE under misspecified models and is clearly depicted in our exper-
imental simulation studies.
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Figure 4: Boxplot of relative bias. N = 16
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Figure 5: Boxplot of relative bias. N = 31
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N = 16 N = 31
n TP MP NP(opt) TP MP NP(opt)
50 0.073 0.209 0.014 0.035 0.178 0.001
(0.0065) (0.0094) (0.0097) (0.0046) (0.0069) (0.0075)
100 0.030 0.168 -0.029 0.016 0.154 -0.018
(0.0045) (0.0067) (0.0069) (0.0033) (0.0048) (0.0053)
200 0.017 0.163 -0.026 0.009 0.149 -0.009
(0.0033) (0.0049) (0.0058) (0.0022) (0.0033) (0.0042)
Table 1: Relative bias (Monte Carlo standard error) of estimating the functional metric L
under various values of n and N . TP refers to true (correctly specified) parametric models;
MP refers to misspecified parametric model. NP refers to non-parametric approximate
normal likelihood method with a Bernstein polynomial of degree M, where M is selected
according to the optimal strategy.
N = 16 N = 31
n Treatment 1 Treatment 2 Treatment 1 Treatment 2
50 4.867 (0.0399) 3.590 (0.0405) 5.585 (0.0660) 3.903 (0.0710)
100 5.200 (0.0338) 3.601 (0.0402) 5.824 (0.0596) 3.793 (0.0641)
200 5.446 (0.0294) 3.657 (0.0407) 6.140 (0.0568) 3.868 (0.0667)
Table 2: Selected value of M (Monte Carlo standard error) in the NP(opt) model, with
critical value α = 0.5.
5 A Case Study: RA Trials
The development of our models has been motivated by the Rheumatoid Arthritis (RA) trails
and so an illustration, we apply the proposed method on the Rheumatoid Arthritis (RA)
Trials data set (Reeve et al. (2013)). The authors collected data from a list of available
literature of randomized, double-blind clinical studies in RA, where all the studies used
methotrexate (MTX) as the baseline treatment. We choose ACR20 as the endpoint, which
is among the most commonly used endpoints for RA. As we do not conduct meta analysis
in this paper, we select studies based on the following rule: for all the treatments (molecule
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× dose) that have more than 40 weeks of observation, we select the study with the largest
number of time points. There are 3 treatment selected from the RA data set to demonstrate
our methods, namely infliximab dose 3 (infilix:3), tocilizumab dose 4(tocili:4) and czp dose
200 (czp:200). As there were several studies that utilized the baseline MTX we report a
meta-analytic analysis in the Appendix of the paper that uses random coefficient models
and an over estimated response rate curve for the MTX is reported.
We fit both parametric exponential decay model (3) and non-parametric Bernstein
polynomial model (6) on the given set of data. For parametric fit, parameter estimates
along with their standard errors are reported in table 3. When we apply the non-parametric
fit on the data, we found that using the strict monotonic Bernstein polynomial, treatment
inflix:3 doesn’t obtain an M value that will exceed α = 0.2 (The largest p-value achieved
for this trial is 0.138). To resolve this somewhat poor fit, one strategy is to use data
augmentation. If we are willing to assume that at week 0 the response rate should be 0, we
can add data point (0, 0) to the original data. Note that most of the treatment do not have
week 0 as observed value. Then we treat it as if we observed (0,0) and apply the monotonic
fit. Another practical strategy is to partially relax the monotonic constraint (iii) as stated
in Section 2. Say, if we allow the Bernstein polynomial to move freely within the first 1/3
knots, the monotonic constraint remains for the last 2/3 of the knots. Using either of these
two strategies, we can have an optimal M selected that would exceed α = 0.2 significance
level. We use the later strategy as we the strict monotonicity may not be required for all
dose response models.
The selected M values are summarized in Table 4. Figure 6 shows both parametric and
nonparametric fit of the data by treatment, the MTX curves serve as the control treatment
for comparison. The grey line corresponding to time interval a = 5 and b = 25. For
demonstration, we also report the results for a longer time interval a = 30 and b = 50.
The estimated L-metric quantity and their bootstrapped confidence interval are presented
in Table 5. Additionally the entire bootstrapped sampling distribution of the L metric is
shown in Figure 7 and Figure 8.
The bootstrap distributions and associated 95% confidence intervals reported in the
figures and the tables reveal several interesting features and advantages of using a functional
15
metric compared to a fixed time comparison of ∆(t) at a fixed t = t0. Notice that the 95%
confidence interval of tocilizu:4 has no over with that of czp:200 and inflix:3 (see Table 5)
indicating that over the entire time interval (5, 25) weeks, the later two drugs perform
significantly better than the first one relative to the baseline treatment MTX. These results
are consistent no-matter parametric or nonparametric models are used. On the other hand,
the performances of czp:200 and inflix:3 are statistically not different (also see Figure 6).
The results for time interval of (30, 50) weeks are similar but they differ by the para-
metric and nonparametric models. Under the nonparametric model, here appears to be a
slight overlap of the 95% intervals for tocilizu:4 and czp:200, as can be seen in Table 5,
but not under parametric model. On the other hand there’s no overlap of the 95% confi-
dence intervals of the L metric when comparing tocilizu:4 and inflix:3, indicating that the
later drug perform better even in the long run when the response curves seem to plateau.
These findings are slightly different from the parametric model based bootstrapped dis-
tributions and associated 95% confidence intervals. As in our simulation studies we have
seen superior and robust performance of the nonparametric models, we feel more comfort-
able reporting results best on the nonparametric models although for this case study, the
estimated response rate curves are very similar.
αˆ βˆ
MTX 0.156 (0.008) 0.398 (0.084)
tocilizu:4 0.489 (0.008) 0.232 (0.019)
czp:200 0.575 (0.008) 0.435 (0.033)
inflix:3 0.614 (0.011) 0.549 (0.126)
Table 3: RA data: parameter estimate in the exponential model
6 Conclusions and Discussions
In this paper, we present a functional metric to assess biosimilarity. Functional metrics
provide stronger evidence in support of or against when comparing two drugs. We also
compare parametric models verse nonparametric model. We show in simulation studies
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tocilizu:4 czp:200 inflix:3
α = 0.2 8 9 9
α = 0.3 8 9 9
α = 0.4 9 9 9
Table 4: Selected M values under different critical values after relaxing the monotonic
constraint.
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Figure 6: Parametric and nonparametric fit of data by treatment, with M selected based
on α = 0.2. Grey vertical line corresponding to time interval (5, 25).
that nonparametric approach provides more flexible model forms and are robust against
model misspecification. In our case study with RA trials, we have shown the added utility
of using functional metric over fixed time point difference of response rates.
Recall that in our models, we have considered Yj(t) ∼ Bin{nj, θj(t)}, for t ≥ 0 (as in
(1)). As an extension of the models, it is possible to allow the number of observations
nj to change over time t as well. To enable that, we denote Sj(t) to be the number of
patients that respond at time t in the jth treatment group. We can then use the following
hierarchical model:
Sj(t) ∼ Poisson (λj(t)) ,
and
Yj(t)|Sj(t) ∼ Bin (Sj(t), θj(t)) .
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Parametric Nonparametric
Lˆ 95% CI Lˆ 95% CI
a = 5, b = 25
tocilizu:4 4.303 (0.187) (3.978,4.605) 4.200 (0.233) (3.830, 4.597)
czp:200 6.516 (0.183) (6.230, 6.835) 6.722(0.220) (6.423 ,7.135)
inflix:3 7.385 (0.275) (6.911,7.769) 7.893 (0.334) (7.377,8.477)
a = 30, b = 50
tocilizu:4 4.620 (0.207) (4.273, 4.974) 4.649 (0.238 ) (4.268, 5.054)
czp:200 6.330 (0.206) (6.002, 6.668) 6.003 (0.279) (5.561, 6.463)
inflix:3 7.120 (0.255) (6.693, 7.548) 6.699 (0.318) (6.248, 7.286)
Table 5: Functional Metric L estimates (bootstrapped s.e.) and 95% confidence interval.
It would be interesting to develop estimation methods for the above extended hierarchical
models using both parametric and nonparametric models.
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Appendix: Random coefficients model for MTX
We notice that the baseline treatment MTX demonstrates a notable variation across dif-
ferent studies in the RA data set, as shown in Figure 9. Therefore, a random coefficients
model could be a good choice to fit the MTX data.
Yij | αi, βi ∼ Bin[nij, θ(tij;αi, βi)]αi
βi
 | µa, µb, σa, σb, σab ∼ lognormal
µa
µb
 ,
σ2a, σab
σab, σ
2
b
 ,
where θ(tij;αi, βi) = αi(1− e−βitij). Denote η = (µa, µb, σa, σb, σab)T . We could obtain the
maximum likelihood estimator of η by a two step procedure.
The the expected value of θ(tij) is
E[θ(tij;αi, βi)] = E[αi(1− e−βitij ]
= E(αi)− E(αie−βitij) (9)
We have
logαi ∼ N(µa, σ2a), logβi ∼ N(µb, σ2b )
logαi | logβi ∼ N(µa|b, σ2a|b),
where µa|b = µa +
σab
σ2b
(logβi − µb) and σ2a|b = σ2a − (σab/σb)2. Therefore the first term on
the RHS of (9) is E(αi) = E(e
logαi) = eµa+σ
2
a/2. The second term on the RHS of (9) can be
write as
E(αie
−βitij) = E
[
E(αie
−βitij | βi)
]
= E
[
e−βitijE(elogαi | logβi)
]
= exp
{
µa − σab
σ2b
µb +
1
2
[
σ2a −
(
σab
σb
)2]}
E
[
exp
(
−βitij + σab
σ2b
logβi
)]
.
(10)
The expectation in the RHS of (10) can be approximated via numerical integration. The
estimates of the random coefficients are summarized in Table 6. A comparison of the
random coefficients and fixed coefficients models is shown in Figure 10.
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µˆa µˆb σˆa σˆb σˆab
Estimate -1.191 -1.55 0.525 0.425 -0.180
s.e. 0.137 0.124 0.098 0.096 0.080
Table 6: MTX: parameter estimates (MLE) of the random coefficients model
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Figure 7: Bootstrapped distribution of L estimates, red lines corresponding to
2.5%,50%,97.5% percentile of the bootstrapped sample. (a = 5, b = 25)
Par − tocilizu:4
Bootstrapped L distribution
Fr
eq
ue
nc
y
3.5 4.0 4.5 5.0 5.5
0
20
40
60
80
10
0
Par − czp:200
Bootstrapped L distribution
Fr
eq
ue
nc
y
5.5 6.0 6.5 7.0
0
50
10
0
15
0
Par − inflix:3
Bootstrapped L distribution
Fr
eq
ue
nc
y
5.5 6.0 6.5 7.0 7.5 8.0
0
50
10
0
15
0
NP − tocilizu:4
Bootstrapped L distribution
Fr
eq
ue
nc
y
3.5 4.0 4.5 5.0 5.5
0
50
10
0
15
0
NP − czp:200
Bootstrapped L distribution
Fr
eq
ue
nc
y
5.5 6.0 6.5 7.0
0
50
10
0
15
0
NP − inflix:3
Bootstrapped L distribution
Fr
eq
ue
nc
y
5.5 6.0 6.5 7.0 7.5 8.0
0
20
40
60
80
10
0
Figure 8: Bootstrapped distribution of L estimates, red lines corresponding to
2.5%,50%,97.5% percentile of the bootstrapped sample. (a = 30, b = 50)
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Figure 9: MTX data by study ID. The dotted line is the fitted line using all the data under
fixed effect model.
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Figure 10: MTX: Comparison of fixed and random coefficient model.
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